Yuichi Ozawa

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Cancer medicine

Therapeutic advances in medical oncology

Cancer immunology, immunotherapy : CII

Medical oncology (Northwood, London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Yuichi Ozawa, Yasuhiro Koh, Tetsunari Hase, Kenji Chibana, Kyoichi Kaira, Kyoichi Okishio, Eiki Ichihara, Shuji Murakami, Mototsugu Shimokawa, Nobuyuki Yamamoto
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L). Therapeutic advances in medical oncology 16 (2024)
Eriko Murakami, Hiroaki Akamatsu, Shunsuke Teraoka, Toshiaki Takakura, Eri Takase, Masanori Tanaka, Takahiro Kaki, Yuhei Harutani, Katsuyuki Furuta, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Yuichi Ozawa, Masanori Nakanishi, Yasuhiro Koh, Toshio Shimokawa, Nobuyuki Yamamoto
Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: A randomized phase II trial. Cancer medicine 13 (4) (2024)
Eriko Murakami, Hiroaki Akamatsu, Shunsuke Teraoka, Toshiaki Takakura, Eri Takase, Masanori Tanaka, Takahiro Kaki, Yuhei Harutani, Katsuyuki Furuta, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Yuichi Ozawa, Masanori Nakanishi, Yasuhiro Koh, Toshio Shimokawa, Nobuyuki Yamamoto
Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: A randomized phase II trial. Cancer medicine 13 (4) (2024)
Yuichi Ozawa, Yasuhiro Koh, Tetsunari Hase, Kenji Chibana, Kyoichi Kaira, Kyoichi Okishio, Eiki Ichihara, Shuji Murakami, Mototsugu Shimokawa, Nobuyuki Yamamoto
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L). Therapeutic advances in medical oncology 16 (2024)
Charles M Rudin, Stephen V Liu, Ross Andrew Soo, Shun Lu, Min Hee Hong, Jong-Seok Lee, Maciej Bryl, Daphne W Dumoulin, Achim Rittmeyer, Chao-Hua Chiu, Ozgur Ozyilkan, Melissa Lynne Johnson, Alejandro Navarro, Silvia Novello, Yuichi Ozawa, Sammi Hiu Tam, Namrata S Patil, Xiaohui Wen, Meilin Huang, Tien Hoang, Raymond Meng, Martin Reck
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Ryota Shibaki, Yuichi Ozawa, Susumu Noguchi, Yusuke Murakami, Eri Takase, Yuichiro Azuma, Masaru Maebeya, Takeya Sugimoto, Atsushi Hayata, Takahiro Hayakawa, Shinya Tamaki, Masanori Nakanishi, Shunsuke Teraoka, Hiroaki Akamatsu
Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib. Cancer medicine 11 (20) (2022)
Yuhei Harutani, Yuichi Ozawa, Eriko Murakami, Koichi Sato, Jun Oyanagi, Hiroaki Akamatsu, Takanori Yoshikawa, Ryota Shibaki, Takeya Sugimoto, Katsuyuki Furuta, Shunsuke Teraoka, Nahomi Tokudome, Atsushi Hayata, Hiroki Ueda, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors. Cancer immunology, immunotherapy : CII 71 (9) (2022)
Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Daichi Fujimoto, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Akihiro Bessho, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical cancer research : an official journal of the American Association for Cancer Research 28 (5) (2022)
Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Jun Oyanagi, Atsushi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Katsuya Endo, Masayuki Higuchi, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers 13 (10) (2021)
Yuichi Ozawa, Takeya Sugimoto, Yuichiro Azuma, Yuhei Harutani, Takanori Yoshikawa, Nobuyuki Yamamoto, Kuninobu Kanai
Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer. BMJ open 10 (7) (2020)
Yuichi Ozawa, Yuhei Harutani, Jun Oyanagi, Hiroaki Akamatsu, Eriko Murakami, Ryota Shibaki, Atsushi Hayata, Takeya Sugimoto, Masanori Tanaka, Toshiaki Takakura, Katsuyuki Furuta, Yuka Okuda, Kouichi Sato, Shunsuke Teraoka, Hiroki Ueda, Nahomi Tokudome, Yuka Kitamura, Junya Fukuoka, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50. Cancer science 112 (1) (2020)
Yuichi Ozawa, Yusuke Amano, Kei Kanata, Hirotsugu Hasegwa, Takashi Matsui, Takuya Kakutani, Takafumi Koyauchi, Masayuki Tanahashi, Hiroshi Niwa, Koshi Yokomura, Takafumi Suda
Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. Medical oncology (Northwood, London, England) 36 (4) (2019)